← Weight · Rx required
The Frontier Stack
Next-generation. Waitlist only.
Tier 3 · Early evidence — investigational
The story
Next-generation, and we're upfront: this one's a waitlist. Retatrutide works on three hormone pathways and early trials look striking, but it isn't FDA-approved yet.
Why this combination
A single investigational molecule — a triple agonist (GLP-1, GIP, glucagon) studied as a potential step beyond today's options.
What to expect
In a phase 2 trial, the highest dose produced roughly a quarter of body weight lost over about a year — among the largest results for any weight medication. But phase 2 is mid-stage and phase 3 trials are ongoing. Held as a waitlist item because it is not approved.
Risks & considerations
As an investigational drug, its full risk profile isn't established — that uncertainty is the main consideration. Trial side effects mostly gastrointestinal, with attention to heart rate and blood sugar. Long-term safety in the general population is unknown.
Sources
- Retatrutide phase 2 obesity trial, NEJM 2023 (not FDA-approved)
What's in the stack
- Retatrutide
More from Weight
Weight · Rx requiredMost popular
The Kickstart Stack
The proven first step.
- Semaglutide + B12 injection
- Insulin syringes
- Alcohol swabs
Available
$149–199/mo
Weight · Rx required
The Heavy Hitter Stack
Dual-action weight support.
- Tirzepatide + B12 injection
- Injection supplies
Available
$229–329/mo
Weight · Rx required
The Needle-Free Stack
All the science, none of the pokes.
- Semaglutide or tirzepatide sublingual drops
Available
$129–159/mo